June 17, 2020 / 11:16 AM / 25 days ago

BRIEF-PTC Therapeutics Announces Initiation Of Phase 2/3 Clinical Trial To Evaluate PTC299 For Treatment Of COVID-19

June 17 (Reuters) - PTC Therapeutics Inc:

* PTC THERAPEUTICS ANNOUNCES THE INITIATION OF A PHASE 2/3 CLINICAL TRIAL TO EVALUATE PTC299 FOR THE TREATMENT OF COVID-19

* PTC THERAPEUTICS INC - WILL INITIATE AN INTEGRATED PHASE 2/3 STUDY IN U.S. IN COMING DAYS WITH ADDITIONAL SITES PLANNED GLOBALLY

* PTC THERAPEUTICS INC - INTEGRATED PHASE 2/3 STUDY WILL EVALUATE EFFICACY AND SAFETY OF PTC299 IN TWO STAGES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below